LorettaMarieItriMD

PubMed

• 104 citations
  Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.
  Aditya Bardia, Sara M. Tolaney, Kevin Punie, Delphine Loirat, Mafalda Oliveira, Kevin Kalinsky, Amelia Zelnak, Philippe Aftimos, Florence Dalenc, Sagar Sardesai, Erika...> ;Annals of Oncology. 2021 Sep 1
• 196 citations
  TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Ch...
  Scott T. Tagawa, Arjun Vasant Balar, Daniel P. Petrylak, Arash Rezazadeh Kalebasty, Yohann Loriot, Aude Flechon, Rohit Jain, Neeraj Agarwal, Manojkumar Bupathi, Philip...> ;Journal of Clinical Oncology. 2021 Apr 30
• 455 citations
  Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
  Aditya Bardia, Sara A. Hurvitz, Sara M Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam M Brufsky, Sagar D Sardesai, Kevin Kalinsky, Amelia Zelnak, Robert...> ;The New England Journal of Medicine. 2021 Apr 21
• 3 citations
  High Body Mass Index and Use of Fentanyl Iontophoretic Transdermal System in Postoperative Pain Management: Results of a Pooled Analysis of Six Phase 3/3B Trials
  Eugene R. Viscusi, Li Ding, J. Bradley Phipps, Loretta M. Itri, Philip R. Schauer> ;Pain and Therapy. 2017 Jun 1
• 6 citations
  Use of Fentanyl Iontophoretic Transdermal System (ITS) (IONSYS®) in the Management of Patients with Acute Postoperative Pain: A Case Series
  Steven Poplawski, Matthew Johnson, Philip Philips, Leopold Eberhart, T. Koch, Loretta M. Itri> ;Pain and Therapy. 2016 Nov 5
• 4 citations
  The Efficacy and Safety of the Fentanyl Iontophoretic Transdermal System (IONSYS ® ) in the Geriatric Population: Results of a Meta-Analysis of Phase III and IIIb Trials
  Eugene R. Viscusi, Li Ding, Loretta M. Itri> ;Drugs & Aging. 2016 Oct 27
• 3 citations
  Fentanyl Iontophoretic Transdermal System (IONSYS®) can be Safely used in the Hospital Environment with X-Rays, Computerized Tomography and Radiofrequency Identificati...
  John Lemke, Edmond Sardariani, Joseph Bradley Phipps, Niki Patel, Loretta M. Itri, James F. Caravelli, Eugene R. Viscusi> ;Advances in Therapy. 2016 Jul 16
• Tesetaxel, an advanced-generation oral taxane, as first-line treatment in women with metastatic breast cancer.
  Schwartzberg LS, Beeram M, Patnaik A, Tolcher AW, Itri L, Olson AL, Seidman AD> ;J. Clin. Oncol.. 2011-05-20
• Dose-ranging study of tesetaxel, a novel oral taxane, administered as second-line therapy at a flat dose to patients with advanced gastric cancer.
  Baker JS, Qureshi A, Itri L, Sun W, Mulcahy MF, Ajani JA> ;J. Clin. Oncol.. 2011-05-20
• 112 citations
  5-Year Survival in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia in a Randomized, Phase III Trial of Fludarabine Plus Cyclophosphamide With or With...
  Susan O'Brien, Joseph O. Moore, Thomas E. Boyd, Loree Larratt, Aleksander B. Skotnicki, Benjamin Koziner, Asher Chanan-Khan, John F. Seymour, John G. Gribben, Loretta ...> ;Journal of Clinical Oncology. 2009 Nov 1
• 105 citations
  LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951)
  Sanjiv S. Agarwala, Ulrich Keilholz, Erard Gilles, Agop Y. Bedikian, Jane Wu, Richard Kay, Cy A. Stein, Loretta M. Itri, Stefan Suciu, Alexander M.M. Eggermont> ;European Journal of Cancer. 2009 Jul 1
• Prognostic impact of baseline LDH on survival independent of tumor burden in advanced melanoma: Results of phase III trial of oblimersen-dacarbazine (OBL-DTIC) vs DTIC.
  Gilles EM, Bedikian AY, Agarwala SS, Wu J, Itri LM, Eggermont AM> ;J. Clin. Oncol.. 2008-05-20
• Long-term survival results of a randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients (pts) with...
  Kirkwood JM, Bedikian AY, Millward MJ, Conry RM, Gore ME, Pehamberger HE, Sterry W, Pavlick AC, Deconti RC, Itri LM> ;J. Clin. Oncol.. 2005-06-01
• Randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients (pts) with advanced malignant melanoma (MM...
  Millward MJ, Bedikian AY, Conry RM, Gore ME, Pehamberger HE, Sterry W, Pavlick AC, De Conti RC, Gordon D, Itri LM> ;J. Clin. Oncol.. 2004-07-15
• 775 citations
  Erythropoietin therapy for acute stroke is both safe and beneficial.
  Hannelore Ehrenreich, Martin Hasselblatt, Christoph Dembowski, Lukas Cepek, Piotr Lewczuk, Michael Stiefel, Hans-Heino Rustenbeck, Norbert Breiter, Sonja Jacob, Friede...> ;Molecular Medicine. 2002 Aug 1
• 13 citations
  The use of epoetin alfa in chemotherapy patients: A consistent profile of efficacy and safety
  Loretta M. Itri> ;Seminars in Oncology. 2002 Jun 1
• 4 citations
  Managing cancer‐related anaemia with epoetin alfa
  Loretta M. Itri> ;Nephrology, Dialysis, Transplantation. 2002 Jan 1
• 65 citations
  Neuroprotective properties of epoetin alfa
  Anthony Cerami, Michael Brines, Pietro Ghezzi, Carla Cerami, Loretta M. Itri> ;Nephrology, Dialysis, Transplantation. 2002 Jan 1
• 28 citations
  Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations.
  Heinz Ludwig, Kanti R. Rai, Joan Bladé, Franco Dammacco, Laurent Degos, Loretta M. Itri, Robert A. Kyle, Vicenzo Liso, Timothy Littlewood, Franco Mandelli, Giovanna Me...> ;The Hematology Journal. 2002 Jan 1
• 3 citations
  Cancer‐related anaemia requires higher doses of epoetin alfa than chronic renal failure replacement therapy
  Loretta M. Itri> ;Nephrology, Dialysis, Transplantation. 2001 Dec 1
• 844 citations
  Impact of Cancer-Related Fatigue on the Lives of Patients: New Findings From the Fatigue Coalition
  Gregory A. Curt, William Breitbart, David Cella, Jerome E. Groopman, Sandra J. Horning, Loretta M. Itri, David H. Johnson, Christine Miaskowski, Susan L. Scherr, Russe...> ;The Oncologist. 2000 Oct 1
• 1136 citations
  Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury.
  Michael Brines, Pietro Ghezzi, Sonja Keenan, Davide Agnello, Nihal C. de Lanerolle, Carla Cerami, Loretta M. Itri, Anthony Cerami> ;Proceedings of the National Academy of Sciences of the United States of America. 2000 Sep 12
• 648 citations
  Chemotherapy-Induced Anemia in Adults: Incidence and Treatment
  Jerome E. Groopman, Loretta M. Itri> ;Journal of the National Cancer Institute. 1999 Oct 6
• 270 citations
  Cancer-related fatigue: guidelines for evaluation and management.
  Russell K. Portenoy, Loretta M. Itri> ;The Oncologist. 1999 Feb 1
• 268 citations
  13-cis-Retinoic Acid and Interferon α -2a: Effective Combination. Therapy for Advanced Squamous Cell Carcinoma of the Skin
  Scott M. Lippman, David R. Parkinson, Loretta M. Itri, Randal S. Weber, Stimson P. Schantz, David M. Ota, Mark A. Schusterman, Irwin H. Krakoff, Jordan U. Gutterman, W...> ;Journal of the National Cancer Institute. 1992 Feb 19
• Join now to see all